Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [11] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [12] Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England
    Miret, Montserrat
    Anderson, Amanda
    Hindocha, Pooja
    Cirneanu, Lorena
    Lymperopoulou, Christina
    Markov, Emanuil
    Kizito, William
    Vegni, Ferdinando Emanuele
    LEUKEMIA RESEARCH, 2023, 127
  • [13] Prognostic factors in second-line therapy for aggressive non-Hodgkin's lymphoma
    Stein, M.
    Chameisi, Z.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 516 - 516
  • [14] PIXANTRONE MONOTHERAPY IN HISTOLOGICALLY CONFIRMED, RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: POST HOC ANALYSIS FROM A PHASE III TRIAL
    Pettengell, R.
    Theocharous, P.
    Cernohous, P.
    Wang, L.
    Singer, J.
    Myint, H.
    HAEMATOLOGICA, 2013, 98 : 132 - 133
  • [15] Rituximab plus ICE as second-line treatment for relapsed and refractory aggressive non-Hodgkin lymphomas
    Panovska-Stavridis, I
    Georgievski, B
    Cevreska, L
    Stojanovski, Z
    Pivkova, A
    Krstevska-Balkanov, S
    Siljanovski, N
    BONE MARROW TRANSPLANTATION, 2005, 35 : S386 - S386
  • [16] Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Choe, Jee H.
    Abdel-Azim, Hisham
    Padula, William, V
    Abou-El-Enein, Mohamed
    JAMA NETWORK OPEN, 2022, 5 (12)
  • [17] Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
    Viardot, Andreas
    Hess, Georg
    Bargou, Ralf C.
    Morley, Nicholas
    Gritti, Giuseppe
    Iskander, Karim
    Cohan, David
    Zhang, Alicia
    Franklin, Janet
    Coyle, Luke
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yamamoto, Go
    Maruyama, Dai
    Asano-Mori, Yuki
    Kaji, Daisuke
    Ananthakrishnan, Revathi
    Ogasawara, Ken
    Stepan, Lara
    Schusterbauer, Claudia
    Rettby, Nils
    Hasskarl, Jens
    Izutsu, Koji
    CANCER MEDICINE, 2022, 11 (24): : 4889 - 4899
  • [19] Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
    Barr, Paul M.
    Miller, Thomas P.
    Friedberg, Jonathan W.
    Peterson, Derick R.
    Baran, Andrea M.
    Herr, Megan
    Spier, Catherine M.
    Cui, Haiyan
    Roe, Denise J.
    Persky, Daniel O.
    Casulo, Carla
    Littleton, Jamie
    Schwartz, Mark
    Puvvada, Soham
    Landowski, Terry H.
    Rimsza, Lisa M.
    Dorr, Robert T.
    Fisher, Richard I.
    Bernstein, Steven H.
    Briehl, Margaret M.
    BLOOD, 2014, 124 (08) : 1259 - 1265
  • [20] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Dang, NH
    Hagemeister, FB
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Jones, D
    Samuels, B
    Samaniego, F
    Younes, A
    Wang, M
    Goy, A
    Rodriguez, MA
    Walker, PL
    Arredondo, Y
    Tong, AT
    Fayad, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4095 - 4102
12345